What do systematic reviews say?

Pre‐emptive antifungal therapy vs empirical antifungal therapy

It is very uncertain whether pre‐emptive antifungal therapy changes proportion of antifungal agent use (other than prophylactic use) compared with empirical antifungal therapy (very low certainty).

• Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer 2022 · Cochrane Headline outcomes only
  RR 0.71 [0.47, 1.05]
  7 studies · 1480 participants
  Very low

Pre‐emptive antifungal therapy vs empirical antifungal therapy

It is very uncertain whether pre‐emptive antifungal therapy changes duration of antifungal use (days) compared with empirical antifungal therapy (very low certainty).

• Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 764 participants
  Very low

Pre‐emptive antifungal therapy vs empirical antifungal therapy

Pre‐emptive antifungal therapy showed no clear difference in all‐cause mortality compared with empirical antifungal therapy (low certainty).

• Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer 2022 · Cochrane Headline outcomes only
  RR 0.97 [0.72, 1.3]
  6 studies · 1459 participants
  Low

Pre‐emptive antifungal therapy vs empirical antifungal therapy

Pre‐emptive antifungal therapy showed no clear difference in mortality ascribed to fungal infection compared with empirical antifungal therapy (low certainty).

• Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer 2022 · Cochrane Headline outcomes only
  RR 0.92 [0.45, 1.89]
  5 studies · 1407 participants
  Low

Pre‐emptive antifungal therapy vs empirical antifungal therapy

It is very uncertain whether pre‐emptive antifungal therapy changes invasive fungal infection detection compared with empirical antifungal therapy (very low certainty).

• Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer 2022 · Cochrane Headline outcomes only
  RR 1.7 [0.71, 4.05]
  7 studies · 1480 participants
  Very low

Pre‐emptive antifungal therapy vs empirical antifungal therapy

• Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1074 participants
  Very low